Ionic Polymers for Medical Device Applications

Ionic polymers bonded to active agents in medical devices offer stable antimicrobial and antithrombotic properties, addressing efficacy issues and manufacturing complexities, enhancing infection prevention and clot prevention while reducing costs.

JP2024541597AActive Publication Date: 2024-11-08BECTON DICKINSON & CO
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024532273
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-22
Filing Date
2022-11-30
Publication Date
2024-11-08
Estimated Expiration
2042-11-30

AI Technical Summary

Technical Problem

Existing medical devices, such as infusion therapy devices, face challenges with antimicrobial and antithrombotic agent efficacy due to lack of chemical bonding, leading to short-lived antibacterial/antifouling properties and complex, costly manufacturing processes.

Method used

Ionic polymers are ionically bonded to active agents like antimicrobial and antithrombotic agents, forming cationic, anionic, or zwitterionic polymers with functional groups, allowing for controlled release and stable antimicrobial and antifouling properties without the need for priming or plasma treatment.

Benefits of technology

The ionic bonding of polymers to active agents provides long-term antimicrobial and antithrombotic protection, reducing bloodstream infections and blood clots, simplifying manufacturing, and reducing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541597000001_ABST
    Figure 2024541597000001_ABST
Patent Text Reader

Abstract

The medical articles formed by ionically bonding an ionic polymer with an active agent provide enhanced properties. The ionic polymer may be one or more of an anionic polymer, a cationic polymer, and a zwitterionic polymer. The device may also include a non-ionic polymer. The medical articles of the present application have antibacterial, antifouling, and / or antithrombotic properties.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THE DISCLOSURE Embodiments of the present disclosure relate generally to medical devices and methods of making the same. More particularly, embodiments of the present disclosure are directed to medical devices having an ionic polymer ionically bonded to an active agent. The active agent may be an antimicrobial and / or antithrombotic agent. [Background technology]

[0002] Infusion therapy medical devices, such as syringe cannulas and catheters used for sampling or drug administration, typically have parts that come into direct contact with infusions and / or bodily fluids that can cause infection. For example, catheter-related bloodstream infections can be caused by microbial colonization, which can occur in patients undergoing treatments involving intravascular catheters and IV access devices. These infections can result in illness and excessive medical costs. Impregnation and / or coating of catheters and IV access devices with various antimicrobial agents (e.g., chlorhexidine, silver, or other antibiotics) is a common approach that has been implemented to prevent these infections.

[0003] Certain blood contact devices have the potential to cause thrombosis. When blood comes into contact with a foreign body, a complex series of events occurs. These include protein deposition, cell adhesion and aggregation, activation of the blood coagulation system, etc. Traditionally, thrombosis has been prevented by the use of anticoagulants such as heparin. The attachment of heparin to potentially thrombogenic polymer surfaces may be achieved using various surface coating techniques.

[0004] Direct impregnation of catheters and / or IV access devices with antimicrobial and / or antithrombotic agents does not result in a chemical bond between the active agent and the polymeric substrate, and therefore the devices may lose their antimicrobial / antifouling efficacy after a short period of time.

[0005] On the other hand, surface coating techniques stabilize (chemically or physically) antibacterial and / or antithrombotic agents on the surface of polymeric substrates to achieve non-elution or controlled release of such active agents. However, these coating techniques usually require priming (e.g., chemical or plasma treatment) of the polymeric substrate, followed by multiple surface coating steps, which complicates the manufacturing process of medical devices and significantly increases the manufacturing costs. Summary of the Invention [Problem to be solved by the invention]

[0006] Thus, there is a need for medical devices that can bind antimicrobial and / or antithrombotic agents, demonstrate controlled release thereof, and achieve antimicrobial and / or antifouling properties over extended periods of time. [Means for solving the problem]

[0007] One or more embodiments are directed to a medical device comprising: The medical device includes an ionic polymer ionically bonded to an active agent; The ionic polymers include one or more of anionic, cationic, and zwitterionic polymers, and optionally non-ionic base polymers; Anionic polymers are carboxylates (-COO - ), sulfonates (-SO3 - ), organic sulfates (-O-SO3 - ), organic phosphates (-O-PO3 - R 1 or -O-PO3 2- ), phenolate (-C6H4-O - ), and thiolate (-S - ) wherein the functional group is selected from one or more of Cationic polymers are phosphonium (-P + (R 1 )(R 2 )(R 3)), imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium functional groups, or the cationic polymer comprises one or more functional groups selected from quaternary ammonium (-N + (R 1 )(R 2 )(R 3 )), phosphonium (-P + (R 1 )(R 2 )(R 3 )) containing two or more functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; Zwitterionic polymers are carboxylate (-COO - ), sulfonates (-SO3 - ), organic sulfates (-O-SO3 - ), organic phosphates (-O-PO3 - R 1 or -O-PO3 2- ), phenolate (-C6H4-O - ), thiolate (-S - ), quaternary ammonium (-N + (R 1 )(R 2 )(R 3 )), phosphonium (-P + (R 1 )(R 2 )(R 3 )) containing two or more functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; R 1 , R 2 , and R 3 independently includes hydrogen, halogen, alkyl, and aryl.

[0008] An additional embodiment is directed to a method of manufacturing a medical device, comprising: The method includes ionically bonding an ionic polymer, an active agent, and, optionally, a non-ionic base polymer; The ionic polymer includes one or more of an anionic polymer, a cationic polymer, and a zwitterionic polymer; Anionic polymers are carboxylates (-COO - ), sulfonates (-SO3 - ), organic sulfates (-O-SO3 - ), organic phosphates (-O-PO3 - R 1 or -O-PO3 2- ), phenolate (-C6H4-O - ), and thiolate (-S - ) wherein the functional group is selected from one or more of Cationic polymers are phosphonium (-P + (R 1 )(R 2 )(R 3 )), imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium functional groups, or the cationic polymer comprises one or more functional groups selected from quaternary ammonium (-N + (R 1 )(R 2 )(R 3 )), phosphonium (-P + (R 1 )(R 2 )(R 3 )) containing two or more functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; Zwitterionic polymers are carboxylate (-COO - ), sulfonates (-SO3 - ), organic sulfates (-O-SO3 - ), organic phosphates (-O-PO3 - R 1 or -O-PO3 2- ), phenolate (-C6H4-O - ), thiolate (-S - ), quaternary ammonium (-N + (R 1 )(R 2 )(R 3)), phosphonium (-P + (R 1 )(R 2 )(R 3 )) containing two or more functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; R 1 , R 2 , and R 3 independently includes hydrogen, halogen, alkyl, and aryl. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 is a plan view of an exemplary medical device; [Diagram 2] FIG. 1 shows an elution profile of a medical device according to one or more embodiments of the present disclosure. [Diagram 3] FIG. 1 shows an elution profile of a medical device according to one or more embodiments of the present disclosure. [Figure 4] FIG. 1 shows an elution profile of a medical device according to one or more embodiments of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Before describing several example embodiments of the invention, it is to be understood that the invention is not limited to the details of construction or method steps set forth in the following description as the invention is capable of other embodiments and of being practiced or carried out in various ways.

[0011] For purposes of this application, the following terms shall have the meanings set forth below.

[0012] Ionic polymers are polymers that contain both covalent and ionic bonds in their molecular structure. The ionically charged functional groups of ionic polymers can include one or more of cationic and anionic functional groups, forming one or more of cationic, anionic, and zwitterionic polymers. Cationic polymers are macromolecules that have a positive charge, which can be inherently present in the polymer backbone and / or side chains. Anionic polymers are macromolecules that have electronegative groups, which can be inherently present in the polymer backbone and / or side chains. Zwitterionic polymers are macromolecules that incorporate both positive and negative charges in the polymer backbone and / or side chains.

[0013] Antimicrobial agents are substances that kill or stop the growth of microorganisms. Antimicrobial agents that can be used to bind to the cationic and / or anionic functional groups of the ionic polymer include any anionic antibiotic (e.g., cloxacillin salts, cefoxitin salts, cefazolin salts, penicillin salts, or derivatives thereof), and cationic antiseptics (e.g., chlorhexidine acetate, chlorhexidine gluconate, silver sulfadiazine, benzalkonium chloride, cetylpyridinium chloride, or derivatives thereof). In addition, quaternary ammonium-containing biocides, guanidine-containing biocides, cationic antimicrobial polymers, antimicrobial peptides or antimicrobial peptide mimetics, antifouling phospholipids or antifouling phospholipid mimetics, and derivatives thereof can be ionically bound to the anionic functional groups of the ionic polymer as well to provide the benefits of enhanced surface properties, including antimicrobial and / or antifouling properties, actively and / or passively.

[0014] An antithrombotic agent is a substance that prevents the formation of thrombus. An anionic antithrombotic agent (e.g., a heparin salt or a derivative thereof) can be ionically bonded to the cationic functional group of an ionic polymer to exert antithrombotic properties.

[0015] Additionally, one of ordinary skill in the art will recognize that either small or large anionic and / or cationic biocides and anticoagulants can be used for binding to the cationic and / or anionic functional groups of the ionic polymer.

[0016] As used herein, the term "active agent" refers to an antimicrobial agent, an antithrombotic agent, or a combination thereof, that is an anionic, cationic, or zwitterionic compound that can be bound to an ionic polymer. Thus, in some embodiments, the active agent provides antimicrobial activity, antifouling activity, or a combination thereof.

[0017] The principles and embodiments of the present disclosure generally relate to ionic polymer devices with improved properties, and methods of making and using them. Medical articles (e.g., catheter tubing) with antimicrobial and / or antifouling properties are provided by ionically binding and stabilizing active agents to provide desirable material properties including antimicrobial, antifouling, and / or antithrombotic properties. Ionic polymers are provided that are ionically bound to antimicrobial / antithrombotic agents to prevent bloodstream infections and thrombosis (such as deep vein thrombosis (DVT) and catheter blockage due to thrombosis), and provide controlled release of said antimicrobial / antithrombotic agents from the medical device. Medical devices are, for example, catheters, extensions, IV tubing, catheter adapters, luer ports, connector bodies, device housings, parts thereof, combinations thereof, and the like.

[0018] In FIG. 1, an exemplary medical device is shown having the shape of a catheter. A tube made from an ionic polymer ionically bonded to an active agent disclosed herein forms a catheter, which is optionally shaped to receive other components to form a vascular access device. The catheter 10 includes a main conduit 12, which is a tube in its as-extruded form. At the distal end, a tip 14 is formed by a tipping process. At the proximal end, a flange 16 is formed to receive other components, including but not limited to a catheter adapter, as required. The exemplary vascular access device may further include a needle in addition to the catheter for accessing a blood vessel.

[0019] In one or more embodiments, the medical device is in the form of a catheter, an extension, an IV tube, a catheter adapter, a luer port, a connector body, a device housing, parts thereof, or a combination thereof. In some embodiments, the catheter comprises a peripherally inserted central catheter (PICC), a peripheral intravenous catheter (PIVC), or a central venous catheter (CVC). In some embodiments, the controlled release of the ionically bound active agent prevents bloodstream infections and deep vein thrombosis.

[0020] In one or more embodiments, the medical device includes an ionic polymer ionically bonded to an active agent. The ionic polymer is selected from one or more of a cationic polymer, an anionic polymer, and a zwitterionic polymer. In some embodiments, the ionic bond between the active agent and the ionic polymer allows for non-elution and / or controlled release of the active agent. Optionally, a non-ionic base polymer may also be included in the medical device. In one or more embodiments, the medical device passively reduces thrombus formation and / or bacterial biofilm formation by ionic repulsion of bacteria, proteins, and blood components.

[0021] The ionic polymer comprises one or more cationic and / or anionic functional groups. In some embodiments, the anionic polymer comprises anionic functional groups. In some embodiments, the anionic polymer comprises at least one anionic functional group, at least two anionic functional groups, or at least three anionic functional groups. In some embodiments, the anionic polymer comprises two or more anionic functional groups, three or more anionic functional groups, or four or more anionic functional groups. In some embodiments, the cationic polymer comprises cationic functional groups. In some embodiments, the cationic polymer comprises at least one cationic functional group, at least two cationic functional groups, or at least three cationic functional groups. In some embodiments, the cationic polymer comprises two or more cationic functional groups, three or more cationic functional groups, or four or more cationic functional groups. In some embodiments, the zwitterionic polymer comprises anionic and cationic functional groups. In some embodiments, the zwitterionic polymer comprises at least one anionic functional group, at least two anionic functional groups, or at least three anionic functional groups. In some embodiments, the zwitterionic polymer comprises at least one cationic functional group, at least two cationic functional groups, or at least three cationic functional groups. In some embodiments, the zwitterionic polymer comprises two or more anionic functional groups, three or more anionic functional groups, or four or more anionic functional groups. In some embodiments, the zwitterionic polymer comprises two or more cationic functional groups, three or more cationic functional groups, or four or more cationic functional groups.

[0022] In one or more embodiments, the cationic functional group (e.g., a functional group having an overall positive charge) may include any suitable cationic functional group known to one of skill in the art. In one or more embodiments, the cationic functional group may be a quaternary ammonium (-N + (R 1 )(R 2 )(R3 )), phosphonium (-P + (R 1 )(R 2 )(R 3 )), imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; R 1 , R 2 , and R 3 In some embodiments, the ionic polymer is a cationic polymer that does not contain a quaternary ammonium group. That is, in one or more embodiments, the cationic polymer is a phosphonium (-P + (R 1 )(R 2 )(R 3 )), one or more cationic functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; R 1 , R 2 , and R 3 independently includes hydrogen, halogen, alkyl, and aryl.

[0023] In other embodiments, the ionic polymer comprises two or more quaternary ammonium (-N + (R 1 )(R 2 )(R 3 )) in which the quaternary ammonium groups are different from each other.

[0024] In some embodiments, two or more cationic functional groups are present in the cationic or zwitterionic polymer. The two or more cationic functional groups may be quaternary ammonium (-N + (R 1 )(R 2 )(R 3 )), phosphonium (-P + (R 1 )(R 2 )(R 3)), imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; R 1 , R 2 , and R 3 independently includes hydrogen, halogen, alkyl, and aryl.

[0025] In one or more embodiments, the anionic functional group (e.g., a functional group having an overall negative charge) may include any suitable anionic functional group known to one of skill in the art. In some embodiments, the anionic functional group is a carboxylate (-COO - ), sulfonates (-SO3 - ), organic sulfates (-O-SO3 - ), organic phosphates (-O-PO3 - R 1 or -O-PO3 2- ), phenolate (-C6H4-O - ), and thiolate (-S - ), and R 1 includes hydrogen, halogen, alkyl, and aryl.

[0026] In one or more specific embodiments, the ionic polymer is an anionic polymer. The anionic polymer may include any suitable anionic polymer known to one of skill in the art. In one or more embodiments, the anionic polymer is a carboxylate (-COO - ) functional groups. In one or more embodiments, the anionic polymer is selected from the group consisting of carboxylated polyurethanes (Becton, Dickinson and Company) and poly(ethylene-co-methacrylic acid) copolymers (e.g., ionomers under the trade name Surlyn™).

[0027] In another embodiment, the anionic polymer is a sulfonate (-SO -In another embodiment, the anionic polymer is selected from the group consisting of sulfonated polyurethanes (Becton, Dickinson and Company) and perfluorosulfonic acid / polytetrafluoroethylene copolymers (e.g., ionomers under the trade name Nafion™).

[0028] In one or more embodiments, the ionic polymer is a zwitterionic polymer that contains both cationic and anionic functional groups. In some embodiments, the zwitterionic polymer is a carboxylate (-COO - ), sulfonates (-SO3 - ), organic sulfates (-O-SO3 - ), organic phosphates (-O-PO3 - R 1 or -O-PO3 2- ), phenolate (-C6H4-O - ), thiolate (-S - ), quaternary ammonium (-N + (R 1 )(R 2 )(R 3 )), phosphonium (-P + (R 1 )(R 2 )(R 3 )), imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium functional groups, and R 1 , R 2 , and R 3 independently includes hydrogen, halogen, alkyl, and aryl.

[0029] In one or more embodiments, the ionic polymer is ionically bonded to the active agent. The active agent may be any suitable active agent known to those skilled in the art. In embodiments where the ionic polymer is an anionic polymer, the active agent is a cationic active agent. In embodiments where the ionic polymer is a cationic polymer, the active agent is an anionic active agent. In embodiments where the ionic polymer is a zwitterionic polymer, the active agent may be an anionic active agent or a cationic active agent, or both. In one or more specific embodiments, the active agent is selected from one or more of anionic active agents and cationic active agents. In some embodiments, the cationic active agent may be selected from one or more of chlorhexidine acetate, chlorhexidine gluconate, silver sulfadiazine, benzalkonium chloride, cetylpyridinium chloride, quaternary ammonium-containing biocides, guanidine-containing biocides, cationic antimicrobial polymers, antimicrobial peptides or antimicrobial peptide mimetics, antifouling phospholipids or antifouling phospholipid mimetics, and derivatives thereof. In some embodiments, the anionic active agent may be selected from one or more of cloxacillin salts, cefoxitin salts, cefazolin salts, penicillin salts, heparin salts, and derivatives thereof. Additionally, one skilled in the art will recognize that either small or large anionic and / or cationic biocides and anticoagulants can be used for binding to the cationic and / or anionic functional groups of the ionic polymer.

[0030] In one or more embodiments, the medical device releases or is configured to release the active agent within a range of 4 hours to 90 days. In some embodiments, the medical device releases or is configured to release the active agent for a period of at least 4 hours, at least 8 hours, at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, at least 120 hours, or at least 144 hours. In some embodiments, the medical device releases or is configured to release the active agent for a period of at least 3 days, at least 7 days, at least 14 days, at least 21 days, at least 30 days, at least 60 days, or at least 90 days.

[0031] In one or more embodiments, the medical device includes an optional non-ionic base polymer. In some embodiments, the non-ionic base polymer is included in the medical device. In other embodiments, the non-ionic base polymer is not included in the medical device. The non-ionic base polymer may include any suitable non-ionic polymer known to those skilled in the art. In some embodiments, the non-ionic base polymer includes one or more of polyurethane, copolyester, polyolefin, polyvinyl chloride, polycarbonate, acrylic copolymer, acetal copolymer, cellulose acetate propionate, acrylonitrile / butadiene / styrene copolymer, high impact polystyrene, thermoplastic elastomer, synthetic rubber, and silicone elastomer.

[0032] In one or more embodiments, a coating comprising an ionically bonded ionic polymer and an active agent is coated onto the medical device body. In some embodiments, the coating comprises one or more ionic polymers ionically bonded to one or more active agents. Also, in some embodiments, the coating comprises one or more non-ionic base polymers. In some embodiments, the coating is formed by co-dissolving the ionic polymer and the active agent in a solvent system to form an ionic bond between the ionic polymer and the active agent. In some embodiments, the solvent system is optimized to prevent damage to the medical device during the coating process. In some embodiments, the solvent system is optimized to obtain a final surface coating layer with a controlled coating thickness by flashing off the solvent after coating the medical device.

[0033] The solvent system for coating may be any suitable solvent system known to those skilled in the art. In one or more embodiments, the solvent system dissolves both the ionic polymer and the active agent. In one or more embodiments, the solvent system does not damage the medical device substrate during the coating process. In one or more embodiments, the solvent system can be flashed off after coating. In one or more embodiments, the solvent system includes methyl ethyl ketone, tetrahydrofuran, acetone, ethyl formate, methyl formate, 1,3-dioxolane, ethyl acetate, 2-propanol, ethanol, methanol, or mixtures thereof.

[0034] In some embodiments, the polymeric carrier comprising at least one ionic polymer can be co-dissolved with at least one active agent in a solvent system to form an ionic bond between the ionic polymer and the active agent. In some embodiments, the polymeric carrier comprising at least one ionic polymer can be co-dissolved with one or more active agents in a solvent system to form an ionic bond between the ionic polymer and the active agent. The coating can then be applied to the surface of the medical device or medical device part.

[0035] In some embodiments, the device body comprises one or more ionic polymers, and the device body is impregnated with one or more active agents. In some embodiments, the device body may also comprise one or more non-ionic base polymers. In some embodiments, imbibing may result in loading of the active agent into the medical device or medical device component by diffusion in addition to ionic bonding.

[0036] In some embodiments, the medical device comprises a compounded mixture. In some embodiments, the compounded mixture comprises an ionic polymer and an active agent. In some embodiments, the compounded mixture comprises one or more ionic polymers ionically bonded to one or more active agents. In some embodiments, the compounded mixture further comprises one or more non-ionic base polymers. In one or more embodiments, the compounded mixture can be molded or extruded to obtain a medical device or a component of a medical device.

[0037] In one or more embodiments, the medical device includes at least one excipient. In some embodiments, the at least one excipient is selected from one or more of heat stabilizers, light stabilizers, antiblocking agents, antioxidants, antistatic agents, impact modifiers, reinforcing agents, flame retardants, mold release agents, foaming agents, colorants, radiopaque carriers, lubricants, and the like. In some embodiments, the medical device may include the excipient in an amount ranging from 0.01 to 50% w / w.

[0038] Another aspect of the present disclosure relates to a method for manufacturing a medical device. In one or more embodiments, the method includes ionically bonding an ionic polymer, an active agent, and optionally a non-ionic base polymer. The ionic bonding can be achieved by any suitable technique known in the art. Non-limiting examples of suitable techniques include bulk mixing and dip-dyeing techniques. In some embodiments, bulk mixing techniques include solvent mixing and thermal compounding techniques.

[0039] In one or more embodiments, the device body comprises an ionic polymer, and ionic bonding comprises impregnating the medical device body with the active agent. In some embodiments, the device body also comprises a non-ionic base polymer. In some embodiments, the device body also comprises an additive. In one or more embodiments, the device body comprises ionic polymer in an amount of 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, 75% w / w or more, or 100% w / w or more. In one or more embodiments, the device body comprises ionic polymer in an amount of 100% w / w or less, 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less. In one or more embodiments, the device body comprises an ionic polymer in an amount of from 0.01% w / w or more to 100% w / w or less, and all values ​​and subranges therebetween (including from 0.5% w / w or more to 75% w / w or less, from 1% w / w or more to 50% w / w or less), all of the foregoing values ​​and subranges including from 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, or 10% w / w or more, to 100% w / w or less, 75% w / w or less, 50% w / w or less, or 25% w / w or less. In some embodiments, the device body comprises an ionic polymer for binding of an active agent, advantageously without the need for priming of the device (e.g., chemical or plasma treatment). Thus, in some embodiments, when the device body includes ionic functional groups, the manufacturing process of the medical device is simplified and the conversion cost is significantly reduced. As used herein, the term "conversion cost" refers to the cost required to load the device with an active agent. In some embodiments, immersion dyeing advantageously provides a medical device in which the active agent is ionically bonded to the surface of the medical device and within the device body.In one or more embodiments, the soaking provides a continuous, long-term supply of active agent from the device. In one or more embodiments, the medical device comprising the ionic polymer is effective in passively reducing clot formation and / or bacterial biofilm without the soaking treatment. In one or more embodiments, the passive reduction of clot formation and / or bacterial biofilm of the ionic polymer is due to ionic repulsion of bacteria, proteins, and blood components.

[0040] In some embodiments, the method further comprises the step of pre-swelling the device body. In some embodiments, the method further comprises the step of deionizing the ionic polymer. In some embodiments, the ionic bond between the ionic polymer and the active agent is formed using a dip-dyeing technique. Thus, in some embodiments, the dip-dyeing method comprises the step of deionizing the ionic polymer prior to dip-dying the device body in a solution of the active agent. In some embodiments, the dip-dyeing technique comprises the step of pre-swelling the device body prior to deionizing the ionic polymer and dip-dying the device body in a solution of the active agent.

[0041] In some embodiments, the process parameters of the dyeing process can be adjusted to optimize the loading and elution of the active agent. Thus, in some embodiments, the process parameters include process temperature, process time, concentration of the active agent, choice of solvent system, or a combination thereof.

[0042] In some embodiments, the step of ionically binding the ionic polymer and the active agent comprises preparing a polymer formulation comprising the active agent. In some embodiments, the polymer formulation comprises the ionic polymer and the active agent. In some embodiments, the polymer formulation further comprises a non-ionic base polymer. In one or more embodiments, the polymer formulation comprises an amount of ionic polymer of 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, 75% w / w or more, or 99.9% w / w or more. In one or more embodiments, the polymer formulation comprises ionic polymer in an amount of 99.9% w / w or less, 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less. In one or more embodiments, the polymer formulation comprises an ionic polymer in an amount of from 0.01% w / w or more to 99.9% w / w or less, and all values ​​and subranges therebetween, including from 0.5% w / w or more to 75% w / w or less, and from 1% w / w or more to 50% w / w or less, all of the foregoing values ​​and subranges including from 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, or 10% w / w or more, to 99.9% w / w or less, 75% w / w or less, 50% w / w or less, or 25% w / w or less. In one or more embodiments, the polymer formulation comprises an amount of active agent that is 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, or 75% w / w or more.In one or more embodiments, the polymer formulation comprises an amount of active agent of 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less. In one or more embodiments, the polymer formulation comprises an active agent in an amount of from 0.01% w / w or more to 75% w / w or less, and all values ​​and subranges therebetween, including from 0.5% w / w or more to 50% w / w or less, and from 1% w / w or more to 25% w / w or less, all of the foregoing values ​​and subranges including from 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, or 5% w / w or more, to 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, or 6.0% w / w or less.

[0043] In one or more embodiments, preparing the polymer formulation may include blending an ionic polymer, an active agent, and optionally a non-ionic base polymer to form an ionically bonded blended mixture. In one or more embodiments, the blended mixture comprises ionic polymer in an amount of 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, 75% w / w or more, or 99.9% w / w or more. In one or more embodiments, the blended mixture comprises ionic polymer in an amount of 99.9% w / w or less, 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less. In one or more embodiments, the blended mixture comprises an ionic polymer in an amount of from 0.01% w / w or more to 99.9% w / w or less, and all values ​​and subranges therebetween, including from 0.5% w / w or more to 75% w / w or less, and from 1% w / w or more to 50% w / w or less, all of the foregoing values ​​and subranges including from 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, or 10% w / w or more, to 99.9% w / w or less, 75% w / w or less, 50% w / w or less, or 25% w / w or less. In one or more embodiments, the formulated mixture comprises an amount of active agent of 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, or 75% w / w or more. In one or more embodiments, the formulated mixture comprises an amount of active agent of 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less.In one or more embodiments, the blended mixture comprises an amount of active agent from 0.01% w / w or more to 75% w / w or less, and all values ​​and subranges therebetween, including 0.5% w / w or more to 50% w / w or less, and 1% w / w or more to 25% w / w or less, all of the foregoing values ​​and subranges including from 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, or 5% w / w or more, to 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, or 6.0% w / w or less. Advantageously, in some embodiments, the blended mixture provides a medical device in which the active agent is ionically bound not only to the surface of the medical device, but also within the body of the device, resulting in a continuous and long-term supply of active agent from the device.

[0044] In some embodiments, the blend of the polymer formulation is processed by a twin-screw compounder. Thus, in some embodiments, a gravimetric multi-feeder system can be used to control and adjust the ratio of one or more of the ionic polymer, active agent, non-ionic base polymer, and additives. The mixture (conveyed through multiple heating and mixing zones) can be passed continuously through a die, a quench tank, and subsequently cut into regular size pellets by a puller-pelletizer. The pellets of the blended polymer formulation can be used for molding and / or extrusion to form a medical device or a part of a medical device. In some embodiments, the process conditions of the twin-screw compounder are optimized to achieve homogeneous mixing of the active agent in the polymer formulation. In some embodiments, homogeneous mixing correlates with a desired elution profile of the active agent from the medical device. In some embodiments, the process parameters of the twin-screw compounder include zone temperatures, screw design, and screw speed (RPM). In some embodiments, the method further includes molding and / or extruding the blended polymer formulation into a medical device. In some embodiments, the medical device is molded and / or extruded by injection molding and / or extrusion techniques.

[0045] In one or more embodiments, preparing the polymer formulation may include solvent mixing an ionic polymer, an active agent, and an optional non-ionic base polymer to form an ionically bonded coating formulation. In one or more embodiments, the coating formulation comprises ionic polymer in an amount of 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, 75% w / w or more, or 99.9% w / w or more. In one or more embodiments, the coating formulation comprises ionic polymer in an amount of 99.9% w / w or less, 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less. In one or more embodiments, the coating formulation comprises an ionic polymer in an amount of from 0.01% w / w or more to 99.9% w / w or less, and all values ​​and subranges therebetween, including from 0.5% w / w or more to 75% w / w or less, and from 1% w / w or more to 50% w / w or less, all of the foregoing values ​​and subranges including from 0.01% w / w or more, 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, or 25% w / w or more, to 99.9% w / w or less, 75% w / w or less, or 50% w / w or less. In one or more embodiments, the coating formulation comprises an active agent in an amount of 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, 5% w / w or more, 10% w / w or more, 25% w / w or more, 50% w / w or more, or 75% w / w or more. In one or more embodiments, the coating formulation comprises an active agent in an amount of 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, 6.0% w / w or less, 4% w / w or less, 2% w / w or less, or 1.0% w / w or less.In one or more embodiments, the coating formulation comprises an amount of active agent in an amount of from 0.01% w / w or more to 75% w / w or less, and all values ​​and subranges therebetween, including from 0.5% w / w or more to 50% w / w or less, and from 1% w / w or more to 25% w / w or less, all of the foregoing values ​​and subranges including from 0.1% w / w or more, 0.5% w / w or more, 1% w / w or more, 1.5% w / w or more, 2% w / w or more, 3% w / w or more, 4% w / w or more, or 5% w / w or more, to 75% w / w or less, 50% w / w or less, 25% w / w or less, 10% w / w or less, 8.0% w / w or less, or 6.0% w / w or less. In some embodiments, the method further comprises applying the coating formulation to a surface of the medical device or medical device part. Advantageously, in some embodiments, such ionically bonded coating formulations simplify the manufacturing process of medical devices and significantly reduce conversion costs. Advantageously, in some embodiments, the coatings allow for the loading of active agents onto the surfaces of conventional medical devices.

[0046] In some embodiments, the process parameters of the coating formulation may be adjusted to optimize the loading and elution of the active agent. Thus, in some embodiments, the process parameters include process temperature, process time, component concentrations, selection of the solvent system, or a combination thereof. EXAMPLES

[0047] Example 1 (Sample preparation) The non-ionic (control) and ionic polymers used in this study are listed in Table 1. Both ribbon sheets and one-lumen tubes were fabricated and tested.

[0048] [Table 1]

[0049] [Table 2]

[0050] Example 2 The following procedure was used to test samples C1, C2, R1, R2, R7, R8, and T4 (listed in Table 1).

[0051] (Sample Dyeing) Each sample (approximately 5 cm 2 A ribbon sheet or a tube of about 5 cm length) was pre-swollen by immersing in a 50 / 50 v / v% methanol / dioxolane solution (C1, C2, R1, R7, R8, T4) or 100% methanol (R2) at room temperature for 30 minutes. Each sample was then immersed in a 50 mM Tris base buffer (90 / 10 v / v% methanol / water) at 35°C for 120 minutes for deprotonation of the ionic functional groups. Each sample was then immersed in 10 mL of methanol at room temperature for 1 minute to wash out the Tris base buffer. Each sample was then immersed in 10 mL of a loading solution. The loading solution contained a methanol / water (30 / 70 v / v%) solution of an activator and was used at 37°C for 24 hours. The activator was chlorhexidine acetate (100 mM) / sodium citrate (1 mM). During the loading process, each sample was placed on an orbital shaker. After the loading process, each sample was immersed in 10 mL of methanol at room temperature for 1 minute to wash off the loading solution. After washing, each sample was dried in a fume hood at room temperature overnight to flush off residual methanol solvent.

[0052] (Chlorhexidine elution in human serum) Each sample spiked with chlorhexidine as described above was immersed in dissolution media containing human serum / phosphate buffered saline (60 / 40 v / v%) at 37°C for time intervals ranging from 3 hours to 20 days (on an orbital shaker at 150 RPM). At each designated time interval, the previous dissolution media was removed for chlorhexidine dissolution analysis and quantification by high performance liquid chromatography (HPLC), and fresh dissolution media was used for the next time interval. The amount of chlorhexidine dissolved is defined as the mass of chlorhexidine dissolved per unit area of ​​sample (units: μg / cm2). 2 ).

[0053] (Extracted after chlorhexidine dissolution) After the dissolution test, the remaining chlorhexidine in each sample was completely extracted (on an orbital shaker at 150 RPM) using an extraction medium containing trifluoroacetic acid / acetonitrile / water (0.3 / 70 / 30 v / v / v%) for 24 hours at 37°C. The remaining chlorhexidine in each sample was then analyzed and quantified by HPLC. The amount of chlorhexidine remaining is defined as the mass of remaining chlorhexidine per unit area of ​​the sample (unit: μg / cm2). 2 ).

[0054] (Calculation of the amount of chlorhexidine carried) The initial amount of chlorhexidine loaded can be calculated by adding the total amount of chlorhexidine eluted (sum of all elution points) and the amount of chlorhexidine remaining (by post-elution extraction).

[0055] Table 2 shows the initial chlorhexidine loading data (average of three replicates) for the control polymer without ionic functional groups and the ionic polymer, using the dip dyeing method described above.

[0056] [Table 3]

[0057] From Table 2, both of the control polymers (C1 and C2) without ionic functional groups showed low loading of chlorhexidine (approximately 50 μg / cm) after dyeing. 2 ) This is due to the fact that the unbound free chlorhexidine was trapped within the polymer matrix during dyeing. However, the ionic polymers (R1, R2, R7, R8 and T4) show much higher loading of chlorhexidine after dyeing due to the ionic interaction between the anionic functional groups and chlorhexidine.

[0058] Table 3 shows data on the amount of chlorhexidine dissolved and remaining in human serum (average values ​​of three replicate tests) for both the control polymer having no ionic functional groups and the ionic polymer.

[0059] [Table 4]

[0060] FIG. 2 shows the integrated elution of chlorhexidine in human serum over a period of time for both the control polymer, which does not have ionic functional groups, and the ionic polymer.

[0061] Table 3 and Figure 2 show the chlorhexidine elution profiles of the control polymer and the ionic polymers without ionic functional groups. For the control polymers without ionic functional groups (C1 and C2), most of the loaded chlorhexidine was eluted in the first 24 hours, and minimal chlorhexidine remained in the polymer matrix after the first day. Thus, the polymers did not show controlled release. For the ionic polymers (R1, R2, R7, R8 and T4), only a small portion of the loaded chlorhexidine was eluted in the first 24 hours. This is presumed to be unbound and / or weakly bound chlorhexidine trapped in the polymer matrix. The remaining chlorhexidine was ionically bound in the polymer matrix and was released slowly.

[0062] Example 3 Samples R1, R2, R4, R7, R8 and T4 (listed in Table 1) were tested according to the following procedure: Unlike in Example 2, a solution of chlorhexidine acetate (400 mM) in methanol was used as the dip dyeing solution instead of a solution of chlorhexidine acetate (100 mM) / sodium citrate (1 mM) in methanol / water (30 / 70 v / v%).

[0063] (Sample Dyeing) Each sample (approximately 5 cm 2 A ribbon sheet or a tube of about 5 cm length) was pre-swollen by immersing in a 50 / 50 v / v% methanol / dioxolane solution (R1, R7, R8, T4) or 100% methanol (R2, R4) at room temperature for 30 minutes. Then, for deprotonation of ionic functional groups, each sample was immersed in a 50 mM Tris base buffer (90 / 10 v / v% methanol / water) at 35°C for 120 minutes. Then, each sample was immersed in 10 mL of methanol at room temperature for 1 minute to wash out the Tris base buffer. Then, each sample was immersed in 10 mL of a loading solution. The loading solution included a methanol solution of chlorhexidine acetate (400 mM) and was used at 37°C for 24 hours. During this loading process, each sample was placed on an orbital shaker. After the loading step, each sample was immersed in 10 mL of methanol at room temperature for 1 min to wash off the loading solution. After washing, each sample was dried in a fume hood at room temperature overnight to flash off residual methanol solvent.

[0064] (Chlorhexidine elution in human serum) Each sample spiked with chlorhexidine as described above was immersed in dissolution media containing human serum / phosphate buffered saline (60 / 40 v / v%) at 37°C for time intervals ranging from 3 hours to 21 days (on an orbital shaker at 150 RPM). At each designated time interval, the previous dissolution media was removed for chlorhexidine dissolution analysis and quantification by high performance liquid chromatography (HPLC), and fresh dissolution media was used for the next time interval. The amount of chlorhexidine dissolved is defined as the mass of chlorhexidine dissolved per unit area of ​​sample (units: μg / cm2). 2 ).

[0065] (Extracted after chlorhexidine dissolution) After the dissolution test, the remaining chlorhexidine in each sample was completely extracted (on an orbital shaker at 150 RPM) using an extraction medium containing trifluoroacetic acid / acetonitrile / water (0.3 / 70 / 30 v / v / v%) for 24 hours at 37°C. The remaining chlorhexidine in each sample was then analyzed and quantified by HPLC. The amount of chlorhexidine remaining is defined as the mass of remaining chlorhexidine per unit area of ​​the sample (unit: μg / cm2). 2 ).

[0066] (Calculation of the amount of chlorhexidine carried) The initial amount of chlorhexidine loaded can be calculated by adding the total amount of chlorhexidine eluted (sum of all elution points) and the amount of chlorhexidine remaining (by post-elution extraction).

[0067] Table 4 shows data on the initial chlorhexidine loading of the ionic polymer by the above-mentioned dip dyeing method (average of three replicate tests).

[0068] [Table 5]

[0069] Compared with Table 2, Table 4 shows that when a methanol solution of chlorhexidine acetate (400 mM) was used as the dip dyeing solution instead of a methanol / water solution of chlorhexidine acetate (100 mM) / sodium citrate (1 mM) in 30 / 70 v / v %, the amount of chlorhexidine loaded on the perfluorosulfonic acid / polytetrafluoroethylene copolymer (R8 and T4) did not change significantly, but the amount of chlorhexidine loaded on the carboxylated polyurethane (R1 and R2) and poly(ethylene-methacrylic acid) copolymer (R7) increased significantly.

[0070] Table 5 shows data on the amount of chlorhexidine dissolved and the amount remaining in human serum from the ionic polymer (average values ​​of three repeated tests).

[0071] [Table 6]

[0072] FIG. 3 shows the cumulative amount of chlorhexidine eluted in human serum over a period of time for an ionic polymer.

[0073] Table 5 and Figure 3 show the chlorhexidine elution profiles of the ionic polymers. The data show that when a methanol solution of chlorhexidine acetate (400 mM) was used as the dip dye instead of a methanol / water solution of chlorhexidine acetate (100 mM) / sodium citrate (1 mM) (30 / 70 v / v%), the amount of chlorhexidine eluted from the perfluorosulfonic acid / polytetrafluoroethylene copolymers (R8 and T4) did not change significantly, but the amount of chlorhexidine eluted from the carboxylated polyurethanes (R1 and R2) was significantly improved.

[0074] Example 4 Samples C3, R1, R2, R3, R4, R5, R6, T1, T2 and T3 (listed in Table 1) were tested according to the following procedure: Unlike in Example 3, the pre-swelling and deprotonation steps were not applied, and the samples were directly dyed in a methanolic solution of chlorhexidine acetate (400 mM).

[0075] (Sample Dyeing) Each sample (approximately 5 cm 2 A ribbon sheet or a tube of about 5 cm length was immersed in 10 mL of the loading solution. The loading solution included a methanol solution of chlorhexidine acetate (400 mM) and was used at 37° C. for 24 hours. Each sample was placed on an orbital shaker during the loading process. After the loading process, each sample was immersed in 10 mL of methanol at room temperature for 1 minute to wash off the loading solution. After washing, each sample was dried in a fume hood at room temperature overnight to flush off the residual methanol solvent.

[0076] (Chlorhexidine elution from human (or bovine) serum) Each sample spiked with chlorhexidine as described above was immersed in dissolution media containing human (or bovine) serum / phosphate buffered saline (60 / 40 v / v%) at 37°C for time intervals ranging from 3 hours to 60 days (on an orbital shaker at 150 RPM). At each designated time interval, the previous dissolution media was removed for chlorhexidine dissolution analysis and quantification by high performance liquid chromatography (HPLC), and fresh dissolution media was used for the next time interval. The amount of chlorhexidine dissolved is defined as the mass of chlorhexidine dissolved per unit area of ​​sample (units: μg / cm2). 2 ).

[0077] (Extracted after chlorhexidine dissolution) After the dissolution test, the remaining chlorhexidine in each sample was completely extracted (on an orbital shaker at 150 RPM) using an extraction medium containing trifluoroacetic acid / acetonitrile / water (0.3 / 70 / 30 v / v / v%) for 24 hours at 37°C. The remaining chlorhexidine in each sample was then analyzed and quantified by HPLC. The amount of chlorhexidine remaining is defined as the mass of remaining chlorhexidine per unit area of ​​the sample (unit: μg / cm2). 2 ).

[0078] (Calculation of the amount of chlorhexidine carried) The initial amount of chlorhexidine loaded can be calculated by adding the total amount of chlorhexidine eluted (sum of all elution points) and the amount of chlorhexidine remaining (by post-elution extraction).

[0079] Table 6 shows data (average of three replicates) on the initial chlorhexidine loading for the control polymer and the ionic polymers without ionic functionality using the dip dyeing method described above.

[0080] [Table 7]

[0081] Similar to the observations in Table 2, Table 6 shows that the control polymer (C3) without ionic functional groups showed low chlorhexidine loading after dyeing. This is due to the unbound free chlorhexidine being trapped within the polymer matrix during dyeing. However, the ionic polymers (R1, R2, R3, R4, R5, R6, T1, T2, T3) showed much higher chlorhexidine loading after dyeing due to the ionic interaction between the anionic functional groups and chlorhexidine. As these ionic polymers are all polyurethane-based materials, generally, the higher the anion content, the higher the chlorhexidine loading. Table 6 also shows that the highly desirable chlorhexidine loading was achieved in a single dyeing step without the need for preswelling and deprotonation steps. Thus, the dyeing process can be significantly simplified. In addition, Table 6 shows that for the same ionic polymer, the tube configurations (i.e., T1, T2, and T3) showed lower chlorhexidine loading compared to the ribbon sheet configurations (i.e., R1, R4, and R6), due to the thinner walls of the tube compared to the thickness of the ribbon sheet, resulting in less mass of material and ionic content per unit area of ​​sample for the tube vs. ribbon sheet.

[0082] Table 7 shows data (average of three replicate tests) on the amount of chlorhexidine dissolved and remaining in human (or bovine) serum for both the control polymer without ionic functional groups and the ionic polymer.

[0083] [Table 8]

[0084] [Table 9]

[0085] FIG. 4 shows the integrated elution of chlorhexidine in human (or bovine) serum over a period of time for both the control polymer having no ionic functional groups and the ionic polymer.

[0086] Table 7 and Figure 4 show the chlorhexidine elution profiles of both the control polymer and the ionic polymers without ionic functional groups. Similar to previous observations, the control polymer without ionic functional groups (C3) did not show controlled release due to low chlorhexidine loading. However, the ionic polymers (R1, R2, R3, R4, R5, R6, T1, T2, T3) showed highly desirable controlled release profiles up to day 60. As these ionic polymers are all polyurethane-based materials, generally, the higher the anion content, the higher the chlorhexidine loading and the higher the daily elution of chlorhexidine. The data also show that a highly desirable controlled release profile of chlorhexidine was achieved with a one-step dyeing process, even if a preswelling and deprotonation process was used. Thus, the dyeing process can be greatly simplified. Additionally, for the same ionic polymer, the tube configurations (i.e., T1, T2, and T3) showed lower chlorhexidine loading compared to the ribbon sheet configurations (i.e., R1, R4, and R6), due to the thinner walls of the tube compared to the thickness of the ribbon sheet in the tube vs. ribbon sheet configurations, resulting in less mass of material, ionic content, and chlorhexidine loading per unit area of ​​sample.

[0087] Example 5 (Antibacterial effect) Sample C1 (listed in Table 1) served as a control. Samples R1, R2, R3, R4 and R6 (listed in Table 1) were dyed for chlorhexidine loading according to the procedure of Example 4.

[0088] (Sample Dyeing) Each sample coupon (R1, R2, R3, R4, and R6, 1.5 cm x 1.5 cm) was immersed in 5 mL of loading solution. The loading solution included chlorhexidine acetate (400 mM) in methanol and was used at 37°C for 24 hours. Each sample was placed on an orbital shaker during the loading process. After the loading process, each sample was immersed in 5 mL of methanol at room temperature for 1 minute to wash off the loading solution. After washing, each sample was dried in a fume hood at room temperature overnight to flush off residual methanol solvent.

[0089] (Antibacterial Test) The antimicrobial efficacy of the dyed coupons (R1, R2, R3, R4, R6) against Candida albicans (yeast), coagulase-negative Staphylococcus epidermidis (gram-positive), and Klebsiella pneumoniae (gram-negative) was tested after 1, 3, 7, and 14 days of pretreatment. The test method can quantitatively measure microbial colonization on and around the sample coupons (both control coupons and dyed test coupons). The sample samples were assembled into the test apparatus and sterilized with ethylene oxide before testing.

[0090] Samples were pretreated with 60% human serum (HS) in phosphate-buffered saline (PBS) for 14 days at 37 ± 2°C under constant agitation. The pretreatment solution was replaced daily with immersion-sterilized 60% HS in PBS.

[0091] After pretreatment in HS for 1, 3, 7 and 14 days, the sample coupons (both control coupons and the stained test coupons) were challenged with the following three microorganisms: (i) Candida albicans (yeast, approximately 1.0 × 10 5 CFU / apparatus); (ii) Coagulase-negative Staphylococcus epidermidis (Gram-positive, approximately 1.0 × 10 5 CFU / apparatus); and (iii) Klebsiella pneumoniae (gram-negative, approximately 1.0 × 10 5 CFU / apparatus). The challenges were incubated under constant agitation for 24 hours at 37±2° C. Tests were performed in triplicate for each microbial challenge at each time point.

[0092] (Collection of airborne bacteria) Twenty-four hours after microbial challenge, the challenge medium was neutralized with D / E neutralizing broth and viable colony forming units (CFU) were quantified by serial dilution and plating on prepared tryptic soy agar (TSA) plates. Plates were incubated at 37 ± 2°C and counted after approximately 16-24 hours. Data were evaluated as total CFU recovered / device. log 10 The reduction was compared with the counts of a control sample (C1).

[0093] (Biofilm recovery) Twenty-four hours after microbial challenge, coupon samples were washed with sterile saline and placed in D / E neutralizing broth. Coupon samples were then sonicated to recover the biofilm attached to the coupon. The recovered biofilm suspension was quantified by serial dilution and plating on prepared tryptic soy agar (TSA) plates. Plates were incubated at 37 ± 2°C and counted after approximately 16-24 hours. Data were evaluated as total CFU recovered / device. log 10 The reduction was compared with the counts of a control sample (C1). Log 10 CFU / apparatus=Log 10 (CFU / instrument+1) Equation (1) Log 10 Decrease value = (Log 10 CFU / Device_Control)-(Log 10 CFU / apparatus_test) Formula (2) % death = (((CFU / device_control)-(CFU / device_control))÷(CFU / device_control))×100 Equation (3)

[0094] Table 8 summarizes the antibacterial test results for reduction of planktonic bacteria and biofilms of three microorganisms at 1, 3, 7, and 14 days after pretreatment with HS.

[0095] [Table 10]

[0096] [Table 11]

[0097] Table 8 shows that after 1, 3, and 7 days of HS pretreatment, all these dyed ionic polymers (R1, R2, R3, R4, R6) showed highly desirable antimicrobial performance (reduction of both planktonic bacteria and biofilm) against all three microorganisms with desirable chlorhexidine elution at days 1, 3, and 7. After 14 days of HS pretreatment, the dyed samples with high ionic content (R2, R4, and R6) showed highly desirable antimicrobial performance (reduction of both planktonic bacteria and biofilm) against all three microorganisms due to not only high chlorhexidine loading but also continued high chlorhexidine elution at day 14. The dyed samples with low ionic content (R1 and R3) still showed desirable antimicrobial performance (reduction of both planktonic bacteria and biofilm) against Staphylococcus epidermidis. However, the low ion content stained samples (R1 and R3) began to show a decline in antibacterial efficacy against Candida albicans and / or Klebsiella pneumoniae due to lower chlorhexidine loading and lower chlorhexidine elution at day 14. Overall, the results indicate that this technology is highly effective for long-term antibacterial applications (e.g., indwelling catheters).

[0098] Throughout this specification, reference to "one embodiment," "a particular embodiment," "one or more embodiments," or "an embodiment" means that a particular feature, structure, material, or characteristic described in connection with an embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrases "in one or more embodiments," "in a particular embodiment," "in one embodiment," or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment of the invention. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments.

[0099] Although the present invention has been described herein with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made to the method and apparatus of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover such modifications and variations as come within the scope of the appended claims and their equivalents.

Claims

1. 1. A method of manufacturing a medical device, the method comprising the steps of ionically bonding an ionic polymer, an active agent, and, optionally, a non-ionic base polymer; The ionic polymer includes one or more of an anionic polymer, a cationic polymer, and a zwitterionic polymer; The anionic polymer is a carboxylate (-COO - ), sulfonate (-SO 3 - ), organic sulfates (-O-SO 3 - ), organic phosphate (-O-PO 3 - R 1 or -O-PO 3 2- ), phenolate (-C 6 H 4 -O - ), and thiolate (-S - ) , The cationic polymer is a phosphonium (-P + (R 1 ) (R 2 ) (R 3 )), imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium functional groups, or the cationic polymer comprises one or more functional groups selected from quaternary ammonium (-N + (R 1 ) (R 2 ) (R 3 )), phosphonium (-P + (R 1 ) (R 2 ) (R 3 )) containing two or more functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; Zwitterionic polymers are carboxylate (-COO - ), sulfonate (-SO 3 - ), organic sulfates (-O-SO 3 - ), organic phosphate (-O-PO 3 - R 1 or -O-PO 3 2- ), phenolate (-C 6 H 4 -O - ), thiolate (-S - ), quaternary ammonium (-N + (R 1 ) (R 2 ) (R 3 )), phosphonium (-P + (R 1 ) (R 2 ) (R 3 )) containing two or more functional groups selected from imidazolium, pyridinium, sulfonium, guanidinium, thiazolium, and quinolinium; R 1 , R 2 , and R 3 independently includes hydrogen, halogen, alkyl, and aryl. A method for manufacturing a medical device comprising the steps of:

2. 10. The method of claim 1, further comprising coating a surface of the medical device with an ionically bonded ionic polymer and active agent, and an optional non-ionic base polymer.

3. The method of claim 1, further comprising blending the ionically bonded ionic polymer and active agent, and optionally a non-ionic base polymer, to form a blended mixture.

4. 2. The method of claim 1, wherein the body of the medical device comprises an ionic polymer and, optionally, a non-ionic base polymer, and the ionic bonding step comprises impregnating the body of the medical device with an active agent.

5. The method for manufacturing a medical device according to claim 1, wherein the ionic bonding step comprises preparing a polymer formulation comprising an ionic polymer, an active agent, and optionally a non-ionic base polymer.

6. Optionally, pre-swelling the body of the medical device; Optionally, deionizing the ionic polymer; molding and / or extruding the polymer formulation to obtain a medical device; The method for manufacturing a medical device according to claim 5, further comprising:

7. The method for producing a medical device according to claim 1 , wherein the active agent comprises one or more of an anionic active agent and a cationic active agent.

8. The method of claim 1 , wherein the active agent is eluted for at least 24 hours.

9. The method of claim 1, wherein the active agent is eluted for at least three days.

10. The method of claim 1, wherein the active agent is eluted for at least 7 days.

11. The method of claim 1, wherein the active agent is eluted for at least 30 days.

12. The method for producing a medical device according to claim 1 , wherein the active agent includes a cationic active agent.

13. The method of claim 1 , wherein the active agent is selected from the group consisting of an antibacterial agent, an antithrombotic agent, or a combination thereof.

14. 13. The method of claim 12, wherein the cationic active agent comprises one or more of chlorhexidine acetate, chlorhexidine gluconate, silver sulfadiazine, benzalkonium chloride, cetylpyridinium chloride, quaternary ammonium-containing biocides, guanidine-containing biocides, cationic antimicrobial polymers, antimicrobial peptides or antimicrobial peptide mimetics, antifouling phospholipids or antifouling phospholipid mimetics, and derivatives thereof.

15. 8. The method of claim 7, wherein the anionic active agent comprises one or more of a cloxacillin salt, a cefoxitin salt, a cefazolin salt, a penicillin salt, a heparin salt, and derivatives thereof.

16. The method for manufacturing a medical device according to claim 1, characterized in that the medical device is molded and / or extruded by injection molding and / or extrusion techniques.

17. 10. The method of claim 1, wherein the medical device is in the form of a catheter, an extension, an IV tube, a catheter adapter, a luer port, a connector body, a device housing, components thereof, or combinations thereof.

18. The method of claim 1 further comprising the step of adding at least one additive.

19. 20. The method for producing a medical device according to claim 18, wherein the at least one additive is selected from the group consisting of heat stabilizers, light stabilizers, antiblocking agents, antioxidants, antistatic agents, impact modifiers, reinforcing agents, flame retardants, release agents, foaming agents, colorants, radiopaque carriers, and the like.

20. The method for producing a medical device according to claim 1, characterized in that the ionic polymer is selected from the group consisting of carboxylated polyurethane, poly(ethylene-co-methacrylic acid) copolymer, sulfonated polyurethane, and perfluorosulfonic acid / polytetrafluoroethylene copolymer.

Citation Information

Patent Citations

  • Item having vitally active surface, method for preventing interaction between exposed item to human body and vitally active agent dosed to human body, and method for giving vitally active surface to hypodermically implantable item

    JP1995016291A

  • Fluorinated polymers and lubricating coatings

    JP2013538247A